STD SCREENING GUIDELINES

Washington State Clinical Laboratory Advisory Council
Originally published: April 1998 Reviewed/Revised: October 2000/March 2005

Who should be screened?

Symptomatic Testing (listed by symptom and organism/syndrome to consider testing for)

Asymptomatic Screening

Women

- Chlamydia trachomatisa*
- Neisseria gonorrhoeaeb (if under age 25 or multiple sex partners)
- Cervical cancer^c (Pap smear)

Pregnant women

See back

Men Who Have Sex with Men

- Syphilis^d (*Treponema pallidum*)
- · Human Immunodeficiency Virus (HIV)e*
- · C. trachomatis urethral and/or rectal infection (see Chlamydia Screening

Guideline

for test method by specimen type)

- N. gonorrhoeae urethral, rectal and/or pharyngeal infection
- Hepatitis A^f and B^{g*} (if immune status is unknown)

Urethritis/Cervicitis

- C. trachomatis*
- N. gonorrhoeae
- Less frequent causes of urethritis:
- Trichomonas vaginalish, herpes simplex virusi
 (HSV)

Genital Ulcers/Inguinal Lymphadenopathy

- Syphilis (T. pallidum)
- HSV
- Chancroid (Haemophilus ducreyi) (rare†)
- Lymphogranuloma venereum^k (*C. trachomatis* LGV serovars L1, L2 & L3) (rare[†])
- Granuloma Inguinale (Donovanosis) (rare†)

Vaginal Infection

- Trichomoniasis (T. vaginalis)
- Candidiasis (Candida albicans)m
- Bacterial vaginosisⁿ

Genital Warts

Human papillomavirus (HPV)°

HIV Disease (see HIV screening guidelines for tests)

- * See screening guidelines for this condition
- † Consider consultation with infectious disease or STD expert
- a Chlamydia trachomatis nucleic acid amplification test (NAAT), nucleic acid hybridization, culture or antigen test (e.g., EIA, DFA)
- b Neisseria gonorrhoeae culture, nucleic acid amplification test (NAAT), or nucleic acid hybridization
- c Cervical cancer Pap test/Pap +HPV test
- d Syphilis nontreponemal antibody screening test (RPR or VDRL) with treponemal confirmatory test (TP-PA or MHA-TP), darkfield
- * HIV HIV antibody screening test with confirmatory test
- f Hepatitis A anti-HAV IgG
- g Hepatitis B hepatitis B surface antigen, core antibody, anti-HBs
- h Thrichomonas vaginalis wet mount, culture, DNA hybridization assay
- ¹ Herpes simplex virus culture, non-rapid antigen detection test, Western blot
- i Chancroid culture
- ^k Lymphogranuloma venereum nucleic acid amplification, culture or complement fixation
- Granuloma inguinale Giemsa or Wright stain
- ^m Candidiasis KOH preparation, wet mount, Gram stain, DNA hybridization, culture
- n Bacterial vaginosis at least three criteria present (homogenous discharge, pH>4.5, positive amine odor test, presence of clue cells -> 20% of epithelial cells)
- Human papillomavirus clinical diagnosis, biopsy
- P Enteric bacteria urine culture
- 9 Enteric pathogens stool culture and ova and parasites examination, Giardia antigen
- r Pthirus pubis presence of lice or nits (eggs) in pubic hair
- s Scabies presence of mites, eggs or feces in mineral oil preparation of skin scrapings

Pelvic Inflammatory Disease

- N. gonorrhoeae
- C. trachomatis*

Epididymitis

- N. gonorrhoeae
- C. trachomatis*
- Enteric bacteria^p

Proctitis/Proctocolitis/Enteritis

- N. gonorrhoeae
- C. trachomatis
- ·HSV
- Syphilis (T. pallidum)
- Enteric pathogens^q patients with HIV may require additional tests

Liver Disease/Syndrome

(see hepatitis screening and testing guidelines)

Ectoparasitic Infections

- · Pediculosis pubis' (Pthirus pubis, pubic louse, "crabs")
- Scables (Sarcoptes scablei)

REFERENCE:

Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines MMWR May 10, 2002; 51 (No. RR-6)

FOR EDUCATIONAL PURPOSES ONLY

The individual clinician is in the best position to determine which tests are most appropriate for a particular patient.

Clinical Prevention Guidelines

The prevention and control of STDs is based on the following five major concepts: a) education and counseling of persons at risk on ways to adopt safer sexual behavior; b) identification of asymptomatically infected persons and of symptomatic persons unlikely to seek diagnostic and treatment services; c) effective diagnosis and treatment of infected persons; d) evaluation, treatment and counseling of sex partners of persons who are infected with an STD; and e) pre-exposure vaccination of persons at risk for vaccine-preventable STDs.

Clinical Considerations: For persons requesting health services for evaluation of an STD, appropriate care consists of the following components (the temporal order of the interventions may vary, depending on the specific case and diagnosis):

- History
- Medical and behavioral risk assessment (Whenever feasible, all sex partners of persons diagnosed with an STD should be tested and/or treated for the condition and other STDs according to risk. In some circumstances, however, partners may need to be treated even if they cannot or will not be examined.)
- Physical examination
- Laboratory investigations
- Diagnosis
- Therapy to cure infection or reduce symptoms
- Counseling and education: Present episode of STD and prevention of future episodes
- Reporting of case when required
- Sex partner identification, notification, evaluation and treatment
- Clinical follow-up when appropriate

Recommended sequence of specimen collection Females

- First void urine (FVU) specimen for Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae(GC) (if urine tests are being used)
- Vaginal secretions: pH, saline/KOH microscopy, test for amines with KOH (whiff test)
- Endocervical swab for culture or other test for gonorrhea (Urine specimen tested by nucleic acid amplification test (NAAT - see reverse for examples) recommended if cervix absent. Urethral swab also acceptable.)
- Endocervical swab for nucleic acid amplification or other test for chlamydial infection
- Pap smear (defer if menstruating)

Males

- Urethral swab for Gram stain and gonorrhea or GC/Chlamydia combined test
- Swab or urine for Chlamydia (if not using combined test)
- If a NAAT for both GC and CT is being used on a urine specimen, no swab is necessary. Otherwise the order should be GC swab; then swab or urine specimen for CT.

Special Populations: Pregnant Women

The following tests should be performed at the first prenatal visit, with additional testing as indicated.

- Voluntary HIV testing. Retesting in the third trimester (preferably before 36 weeks' gestation) is recommended for women at high risk for acquiring HIV infection.
- A serologic test for syphilis at the time of first examination
- A serologic test for hepatitis B surface antigen (HBsAg) should be performed on all women at the first prenatal visit and repeated late in pregnancy for women at high risk of hepatitis B infection.
- Chlamydia trachomatis. Repeat during the third trimester for women aged<25 years and women with a new, or more than one sex partner.
- Neisseria gonorrhoeae for women at risk. Repeat during third trimester if risk continues.
- A test for hepatitis C antibodies (anti-HCV) for women with a history of injection drug use, repeated exposure to blood products, prior blood transfusion or organ transplants.
- · A Papanicolaou (Pap) smear

For specific recommendations in cases of sexual assault or child abuse, see "Sexual Assault and STDs," Sexually Transmitted Diseases Treatment Guidelines, MMWR May 10, 2002; 51 (No. RR-6): 69-70.